Researchers at St. Jude have identified a set of twenty two markers that predicts minimal residual disease in B-lineage acute lymphoblastic leukemia (ALL) patients. MRD detection by flow cytometry with these antibodies correlated well with those of molecular testing, which is more expensive and requires technical expertise. When used in 6-marker combinations, the new markers can detect one leukemic cell among 100,000 bone marrow cells, as compared to standard 4-color cytometry that detects one leukemic cell in 10,000 normal cells.
Minimal residual disease, assay, detection, antibody
Granted Patents or Published Applications
International application published on Oct 4, 2012 as WO 2012/134813
Related Scientific References
Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui CH, Downing JR, Campana D; New markers for minimal residual disease detection in acute lymphoblastic leukemia; Blood. 2011 Apr 12.
We are currently seeking licensing opportunities in all fields for the development of this technology.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.